main content start
Victoza (liraglutide) injection is a once-daily medication in the GLP-1 receptor agonist class of drugs. It is used in adults and children 10 years of age and older with type 2 diabetes, along with diet and exercise, to improve glucose management. It is also used to reduce the risk of major cardiovascular events such as heart attack, stroke, or death in adults with type 2 diabetes and known heart disease. It helps to release insulin and lowers the amount of glucose produced by the liver when glucose rises at mealtime. It also slows the absorption of mealtime blood glucose.
- Helps manage blood glucose in people with type 2 diabetes 10 years of age and older.
- Use can result in weight loss. Liraglutide is separately approved under the brand name Saxenda to treat obesity.
- Has shown benefits in reducing major cardiovascular events (e.g., heart attack, stroke) in adults with type 2 diabetes and high cardiovascular risk
- Administered as a once-daily subcutaneous injection
- Common side effects include nausea, injection site reactions, and diarrhea or constipation.
Victoza Specs
Key specification
Generic Name
Liraglutide
Approved for Kids
10+ with type 2 diabetes
Drug Class
GLP-1 receptor agonists
Type
Injected
General Information
Product Name
Victoza
Product Type
Injectable Medications
Brand
Novo Nordisk
Other Devices & Supplies
Looking for a different way to manage diabetes care? Browse and compare information on the latest devices, tools, and technology.
